BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32512672)

  • 1. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
    Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
    Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
    Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
    Blood; 1995 Jan; 85(2):588-96. PubMed ID: 7529066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
    Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
    Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?
    Solmaz Medeni Ş; Türkyılmaz D; Acar C; Sevindik ÖG; Yüksel F; Pişkin Ö; Özcan MA; Demirkan F; Ündar B; Alacacıoğlu İ; Özsan GH
    Turk J Haematol; 2018 Nov; 35(4):271-276. PubMed ID: 29923493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
    Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks C; Wong R; Manoharan A; Kwan YL
    Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre.
    Bai L; Xia W; Wong K; Reid C; Ward C; Greenwood M
    Ann Hematol; 2014 Oct; 93(10):1655-64. PubMed ID: 24870941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
    De Rosa L; Anghel G; Pandolfi A; Riccardi M; Amodeo R; Majolino I
    Int J Hematol; 2004 Jan; 79(1):85-91. PubMed ID: 14979484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue.
    Millar BC; Millar JL; Bell JB; Raje N; Milan S; Mehta J; Singhal S; Middleton GW; Sheperd V; Catovsky D; Powles RL
    Bone Marrow Transplant; 1996 Nov; 18(5):871-8. PubMed ID: 8932839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
    Badros A; Barlogie B; Siegel E; Roberts J; Langmaid C; Zangari M; Desikan R; Shaver MJ; Fassas A; McConnell S; Muwalla F; Barri Y; Anaissie E; Munshi N; Tricot G
    Br J Haematol; 2001 Sep; 114(4):822-9. PubMed ID: 11564069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
    Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term hematopoietic engraftment after autologous peripheral blood progenitor cell transplantation in pediatric patients: effect of the CD34+ cell dose.
    Diaz MA; Vicent MG; Garcia-Sanchez F; Vicario JL; Madero L
    Vox Sang; 2000; 79(3):145-50. PubMed ID: 11111232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma.
    Raina V; Sharma A; Kumar R; Bhargava M
    Cancer; 1996 Mar; 77(6):1073-8. PubMed ID: 8635126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma.
    Kazmi MA; Ahsan G; Schey SA
    Clin Lab Haematol; 2001 Apr; 23(2):125-9. PubMed ID: 11488852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients.
    Chhabra S; Thapa B; Szabo A; Konings S; D'Souza A; Dhakal B; Jerkins JH; Pasquini MC; Johnson BD; Hari PN; Hamadani M
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2011-2017. PubMed ID: 32717431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.